Psychedelics in Parkinson's disease and related disorders - A patient perceptions study


Psychedelics are drugs that scientists are studying to see if they can help people who are struggling with mental health issues. Like anxiety, addiction, and post-traumatic stress disorder. Some of the drugs include MDMA, LSD, and psilocybin. This study wants to learn the opinion, knowledge, interest, and concerns of people with Parkinson's Disease. The findings could help create new treatments.

About 20 people with Parkinson's Disease will take part in this study at the University of Calgary. During the study, participants will answer questions from an in-depth interview. First, they will give some information about their medical history and medications. Then, they will ask about their curiosity and any stigma they might feel about psychedelics. After that, they will answer questions about their general knowledge of psychedelics. Then, about their interest in them, and how open they are when discussing these treatments with their doctors. Finally, about their overall opinions and perceptions.

If you want to take part in the study, will have at least 24 hours to consider the information. So that you can discuss it with family members or health providers before consenting to participate in the study.

Your participation in the study will last approximately 20 minutes to 1 hour. You can choose to be interviewed over the phone, on Zoom, or in person. This study is important because it will help care providers understand the needs and curiosities of patients.


Currently recruiting participants: Yes

Eligible gender: Male, Female, Transgender, Other

Eligible ages: 18 to 100

Inclusion criteria:

Inclusion requirements include:
1- Any age diagnosed with Parkinson's Disease at any stage of the disease
2- People with Parkinson's Disease and cognitive impairment or dementia will be included if they are accompanied by a care partner that can support them through the study visits and provide needed information.

Exclusion criteria:

No exclusion criteria for the participants of the study.


Fill out the following form if you want to participate in this research

Method of contact

Additional information

Contact information

Dr. Veronica Bruno Movement Disorders Program Foothills Medical Centre, Area 3

Principal investigator:

Veronica Bruno

Clinical trial: